Posts by: Alice Melao

News

The U.S. Food and Drug Administration approved Genentech’s subcutaneous formulation of Actemra (tocilizumab) to treat patients 2 and older who have active polyarticular juvenile idiopathic arthritis (PJIA). The new Actemra ... Read more

May 11, 2018May 11, 2018

Enbrel Biosimilar Seeks Approval in Japan to Treat Juvenile Idiopathic Arthritis

News

YL Biologics in collaboration with Kyowa, a subsidiary Lupin, are seeking approval from regulatory officials in Japan of YLB113, their potential treatment for patients with moderate-to-severe juvenile idiopathic arthritis and rheumatoid ... Read more

April 12, 2018April 12, 2018

Study Reveals Immune Processes Involved in Systemic Juvenile Arthritis

News

Anomalies in the number of immune cells and specific cellular signals are both linked to the severity of systemic juvenile idiopathic arthritis (JIA) symptoms, researchers in China found. According to ... Read more

March 16, 2018March 16, 2018

Researchers Identify Genetic Sequence Linked to Uveitis Risk in Girls with Juvenile Arthritis

News

Nearly one in three children with the most common forms of juvenile idiopathic arthritis develop a visual disorder called uveitis. To better understand the cause of uveitis, researchers in a recent study ... Read more

February 5, 2018February 5, 2018

Specific Blood Protein May Help Predict Response to Juvenile Arthritis Treatment

News

Measuring the levels of a specific protein in the blood before starting treatment with disease-modifying anti-rheumatic drugs may help predict patients’ response to therapy, according to a recent study published ... Read more

January 31, 2018January 31, 2018

Weekly Doses of Adalimumab Are Safe for Juvenile Arthritis and Uveitis Patients, Study Shows

News

Weekly doses of adalimumab are a safe treatment for juvenile arthritis patients or children with chronic eye inflammation, a study reports. Adalimumab, sold as Humira and under other brand names, is ... Read more

January 19, 2018January 19, 2018

Study Identifies Juvenile Arthritis Patients Most Likely to Respond to NSAID Therapies

News

Juvenile arthritis patients younger than 8 whose disease is less advanced and who have lower levels of an inflammation marker are the likeliest to respond to a stand-alone, non-steroid anti-inflammatory ... Read more

January 5, 2018January 5, 2018

Mental Disorders Are Common Among Children with Juvenile Arthritis, Other Chronic Diseases, Study Finds

News

More than half of children with diabetes, asthma, juvenile arthritis and other diseases have mental health problems, a Canadian study suggests. The research, “Mental disorder in children with physical conditions: ... Read more

December 13, 2017December 13, 2017

RoActemra, IL-1 Inhibitors Better Than Enbrel to Manage JA, Study Suggests

News

RoActemra (tocilizumab) or IL-1 inhibitors are more effective than Enbrel in managing and promoting remission in patients with juvenile idiopathic arthritis (JIA), according to a study published in the journal ... Read more

November 17, 2017November 17, 2017

US Phase 3 Trial Evaluating Efficacy of Sobis’ Kineret Gets Underway

News

The first patients have started receiving treatment in a Phase 3 trial evaluating the therapeutic potential of Kineret (anakinra) for adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA). AOSD ... Read more